BioNTech acquires GMP manufacturing site in Singapore

By Rachel Arthur contact

- Last updated on GMT

Pic:getty/markrubens
Pic:getty/markrubens

Related tags: BioNTech, Singapore, Vaccine, cell and gene therapy, cell and gene therapies, mRNA

BioNTech will create an mRNA facility in Singapore through the acquisition of a Novartis site: which will become its Regional Headquarters and production center for the Asia Pacific region.

The facility is expected to be fully operational late next year, creating more than 100 jobs and supporting BioNTech’s growing pipeline of mRNA-based vaccines and therapeutic at both clinical and commercial scale.

Dr Sierk Poetting, Chief Operating Officer of BioNTech, said: “We are excited to be moving a step closer to expanding our global manufacturing network to Singapore, supporting production of mRNA-based vaccines and therapeutics for the Asia Pacific region.

“The acquisition gives us the opportunity to accelerate the establishment of a state-of-the-art mRNA manufacturing facility and thus to create capacity more quickly for potential clinical studies and commercial supply of our mRNA vaccines and therapeutics for the region.

“In the coming months, we will work closely with all parties on the smooth transition of the site as we continue to prepare for the launch.”

BioNTech’s Singapore mRNA facility will create regional manufacturing capacities in support of mRNA-based vaccines and therapeutics across the Asia Pacific region, with the potential to expand the production to other drug classes, such as cell therapies.

The facility will be initially equipped to manufacture a range of mRNA-based product candidates as well as authorized vaccines and therapeutics for infectious diseases.

This could include the Pfizer/BioNTech COVID-19 vaccine, as well as future oncology product candidates.

The site will be a fully integrated mRNA manufacturing facility bringing mRNA production capabilities across drug substance and drug product, with an expected annual production capacity of up to several hundred million doses of mRNA-based vaccines after a full built-out.

It is expected to create more than 100 jobs in Singapore by 2024 across multiple functions, including operations, engineering, quality, finance, human resources, as well as supply chain management, with recruiting starting immediately for first positions.

The plant, acquired from Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd and supported by the Singapore Economic Development Board, will be part of BioNTech’s affiliate BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. and be fully integrated into the company’s global manufacturing network.

The Singapore Economic Development Board says BioNTech’s investment in Singapore demonstrates ‘confidence in the strong talent base and deep manufacturing capabilities’ of the biopharmaceutical ecosystem.

Sanofi is in the process of building a new $475m vaccine facility in Singapore​ while Merck announced earlier this year it would invest $500m to add capabilities for biologics and vaccine at its manufacturing hub​. In July, WuXi Biologics announced it would build a CRDMO center in Singapore.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Related suppliers

Follow us

Products

View more

Webinars